November 3, 2015 / 4:21 PM / 2 years ago

BRIEF-Genmab raises year forecasts after Q3 results

Nov 3 (Reuters) - Danish biotech Genmab :

* Q3 operating profit 142.68 million Danish crowns ($20.96 million) versus 139 million Danish crowns in same quarter last year

* Says now sees 2015 revenue to be in the range of 725-800 million Danish crowns, an increase of 75 million Danish crowns

* Says revenue at 277.77 million Danish crowns versus 272 million Danish crowns in same quarter last year

* Says improving its 2015 financial guidance due to increased revenue and lower operating expenses resulting in increased operating income and cash position

* Says has increased projected Daratumumab milestones to 240-300 million Danish crowns from the prior estimate of 200-260 million Danish crowns

* Says if Daratumumab receives FDA approval, Genmab will receive a milestone payment from Janssen of $45 million associated with the first commercial sale of the product in the United States <Source text for Eikon: > Further company coverage: ($1 = 6.8072 Danish crowns) (Reporting By Annabella Nielsen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below